Psychedelic therapy

Sage Institute Welcomes Dr. Deidra Somerville as New Executive Director

Retrieved on: 
Thursday, April 28, 2022

OAKLAND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Sage Institute for Psychedelic Therapy , a 501c3 non-profit which provides high-quality training and accessible psychedelic therapy to underserved communities, today announced the arrival of its new executive director, Dr. Deidra Somerville.

Key Points: 
  • OAKLAND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Sage Institute for Psychedelic Therapy , a 501c3 non-profit which provides high-quality training and accessible psychedelic therapy to underserved communities, today announced the arrival of its new executive director, Dr. Deidra Somerville.
  • "On behalf of the Sage Institute board of directors, we welcome Dr. Deidra Somerville as our incoming executive director, said Kat Conour, Sage Institute for Psychedelic Therapy board chair.
  • Somervilles top priorities for the next three months are to:
    I'm honored and excited to join Sage Institute, said Somerville.
  • About Sage Institute for Psychedelic Therapy, Inc
    Sage Institute provides high-quality training and accessible psychedelic therapy, fostering effective and culturally-responsive mental health treatment for underserved communities.

Sage Institute for Psychedelic Therapy Announces Leadership Changes

Retrieved on: 
Wednesday, December 22, 2021

Dr. Herzberg is also one of the owners of Sage Integrative Health, a for-profit therapy clinic, separate from Sage Institute, and a clinician on the MAPS MDMA Phase III Clinical Trials.

Key Points: 
  • Dr. Herzberg is also one of the owners of Sage Integrative Health, a for-profit therapy clinic, separate from Sage Institute, and a clinician on the MAPS MDMA Phase III Clinical Trials.
  • Sage Institute would not have been able to accomplish all that it has without Genesees determination, visionary leadership and many sacrifices, said Kat Conour, Sage Institutes board chair.
  • Sage Institute is one of the only sliding-scale, psychedelic-assisted therapy clinics in the country right now, and were incredibly proud of that.
  • About Sage Institute for Psychedelic Therapy, Inc.
    Sage Institute provides high-quality training and accessible psychedelic therapy, fostering effective and culturally responsive mental health treatment for underserved communities.

Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK

Retrieved on: 
Wednesday, August 4, 2021

Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions.

Key Points: 
  • Awakn Clinics London will join Awakn Clinics Bristol as the only clinics in the world providing evidence backed Ketamine-Assisted Psychotherapy for Alcohol Use Disorder.
  • Awakn Clinics London, a 5,000 square-foot, 8 treatment room clinic, will deliver psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies.
  • Awakn Clinics London will be owned and operated by Awakn and will be led by on-site psychiatrists.
  • Awakn Clinics London will be the second of three Awakn clinics to open this year in the UK.

DTx Producer Entheo Digital Will Present at the July Psychedelic Capital Event, Hosted by Microdose

Retrieved on: 
Wednesday, July 28, 2021

Austin, Texas--(Newsfile Corp. - July 28, 2021) - On Thursday, July 29th, newly founded Digital Therapeutics company will be giving a presentation at Microdose's Psychedelic Capital Event.

Key Points: 
  • Austin, Texas--(Newsfile Corp. - July 28, 2021) - On Thursday, July 29th, newly founded Digital Therapeutics company will be giving a presentation at Microdose's Psychedelic Capital Event.
  • "Psychedelic Therapy is the most important movement in mental health right now, and it's coming at a truly critical moment.
  • These medicines are necessary to support massive psychological healing," says Robin Arnott, CEO of Entheo Digital.
  • Arnott and Maxson will be sharing insights into the powerful role that digital experiences, or "technodelics," can play in psychedelic healing.

Silo Pharma To Appear On National Media Broadcast on Psychedelics

Retrieved on: 
Wednesday, July 21, 2021

The company has sponsored Radio Media LLC to facilitate the interviews to increase awareness of the potential benefits of psychedelic medicines.

Key Points: 
  • The company has sponsored Radio Media LLC to facilitate the interviews to increase awareness of the potential benefits of psychedelic medicines.
  • These benefits may include a wide range of conditions like mental illness, depression, chronic pain, rare neurological conditions, and inflammation.
  • The radio media tour will broadcast on stations across the United States and will include both nationally and regionally-focused programs.
  • Dr. Josh Woolley, MD, PHD, the Director of the Translational Psychedelic Research (TrPR) Program and a Scientific Advisor Board Member of Silo Pharma will be participating in the program.

MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound

Retrieved on: 
Tuesday, July 13, 2021

The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.

Key Points: 
  • The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine.
  • The identified routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds.
  • The two chemical synthesis routes are currently being assessed to determine which one will be selected for further development first.
  • "Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy.

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Inclu

Retrieved on: 
Wednesday, July 7, 2021

Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.

Key Points: 
  • Dr. Ross is an Associate Professor of Psychiatry at NYU Langone, and the Associate Director of its newly designated Center for Psychedelic Medicine.
  • Dr. Ross research principally focuses on the use of psilocybin and related psychedelics for the treatment of mood disorders in patients with life-threatening cancer.
  • As part of the collaboration, the parties will continue to explore the role of psychedelics in the treatment of mental illness in other life-threatening disorders, in addition to cancer.
  • Importantly, we believe that psilocybin is a promising treatment for anxiety and depression in patients with life-threatening cancer, increasing therapeutic opportunities.

Goodness Growth Holdings Subsidiary Resurgent Biosciences Files Patent for Virtual Reality Applications to Facilitate Therapeutic Psychedelic Experiences

Retrieved on: 
Monday, June 28, 2021

To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.

Key Points: 
  • To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.
  • "We believe that VR programs allow practitioners to better prepare and guide patients through their experiences and may optimize therapeutic approaches with psychedelic medicines."
  • Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world.
  • The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences.

Ketamine One Highlights Psychedelic Research and Announces New Clinical Trial

Retrieved on: 
Thursday, June 17, 2021

KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.

Key Points: 
  • KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.
  • Being at the forefront of psychedelics research strongly positions Ketamine One and KGK to generate defendable intellectual property and secure first mover advantages.
  • Further, the Company is pleased to report that KGK has recently been awarded a new clinical trial contract, a research project and has also completed two studies.
  • Developing a network of vertically-integrated clinics within Ketamine One for the conduct of psychedelic clinical trials.

MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression

Retrieved on: 
Thursday, June 17, 2021

These proprietary protocols were developed for MINDCURE by Dr. Mitch Earleywine, Professor of Psychology at the University at Albany, SUNY, and Co-Founder at Wisdom In Nature Consulting Group.

Key Points: 
  • These proprietary protocols were developed for MINDCURE by Dr. Mitch Earleywine, Professor of Psychology at the University at Albany, SUNY, and Co-Founder at Wisdom In Nature Consulting Group.
  • Dr. Earleywine has over 250 papers published in peer-reviewed journals that address psychedelic-assisted treatments, substance abuse, depression, health, and personality.
  • Part of our strategic model is to be the distribution network of the psychedelic-assisted psychotherapy industry, enabling scalable treatment by using iSTRYM's science-backed, evidence-based protocols and AI data systems,"said Kelsey Ramsden, MINDCURE President and CEO.
  • "Delivering on this milestone - having ketamine-enhanced psychotherapy protocols available through our digital therapeutics platform - confirms our end-to-end care model.